All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
ASH 2020 | Practice-changing abstracts in acute myeloid leukemia
By Agnieszka Wierzbowska, Andrew Wei, Charles Craddock, Courtney DiNardo, Eduardo Rego, Eunice Wang, Gail J. Roboz, Gert Ossenkoppele, Gunnar Juliusson, Hee-Je Kim, Hwei-Fang Tien, Isolda Fernandez, Jeffrey Lancet, Jorge Cortes, Jorge Sierra, Lars Bullinger, Naval Daver, Norbert Vey, Selina Luger, Uwe Platzbecker, Yasushi Miyazaki
Did you miss ASH 2020? The AML Hub was pleased to virtually attend the 62nd ASH Annual Meeting & Exposition, December 5-8 2020, and has developed a downloadable resource on the practice-changing abstracts in acute myeloid leukemia (AML).
In this resource, you will find comments from the AML Hub Steering Committee members on improving frontline treatment for patients who are eligible and ineligible for chemotherapy, management of high-risk AML in the era of targeted therapies, maintenance, and novel targeted combinations and how they should be sequenced.
ASH 2020 | Practice-changing abstracts in acute myeloid leukemia
If you would like to view the practice-changing abstracts from ASH 2020 and the expert opinions from our Steering Committee, please download the resource below.
Download hereMore about...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox